Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial - Concepedia

Concepedia

Publication | Open Access

Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial

DOI Full Paper Access

78

Citations

29

References

2012

Year

Mark A. Socinski, Thomas E. Stinchcombe, Dominic T. Moore, Scott Gettinger, Roy H. Decker, W. Jeffrey Petty, A. William Blackstock, Garry Schwartz, Scott P. Lankford, Amir H. Khandani,

Journal of Clinical Oncology

Abstract

The use of bevacizumab and erlotinib as administered in this trial is not recommended given the lack of an efficacy signal and the substantial risk of esophageal toxicity.

References

	Year	Citations

Page 1